Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Virchow Lymph Node Metastatic Recurrence of Sigmoid Colon Cancer with Severe Lymph Node Metastases Successfully Treated Using Systemic Chemotherapy Combined with Radiotherapy

TAKAFUMI OHCHI, YOSHITO AKAGI, TETSUSHI KINUGASA, YOSHIAKI ISHIBASHI, NATSUKI TANAKA, SHINYA FUJINO, SHIRO KIBE, KOTARO YUGE, TERUO SASATOMI, TOMOAKI MIZOBE, YOSUKE OKA, KAWANG DAE HONG and KAZUO SHIROUZU
Anticancer Research July 2013, 33 (7) 2935-2940;
TAKAFUMI OHCHI
1Department of Surgery, Faculty of Medicine, Kurume University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ohchi_takafumi@med.kurume-u.ac.jp
YOSHITO AKAGI
1Department of Surgery, Faculty of Medicine, Kurume University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TETSUSHI KINUGASA
1Department of Surgery, Faculty of Medicine, Kurume University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIAKI ISHIBASHI
1Department of Surgery, Faculty of Medicine, Kurume University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NATSUKI TANAKA
1Department of Surgery, Faculty of Medicine, Kurume University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINYA FUJINO
1Department of Surgery, Faculty of Medicine, Kurume University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIRO KIBE
1Department of Surgery, Faculty of Medicine, Kurume University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOTARO YUGE
1Department of Surgery, Faculty of Medicine, Kurume University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TERUO SASATOMI
1Department of Surgery, Faculty of Medicine, Kurume University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMOAKI MIZOBE
1Department of Surgery, Faculty of Medicine, Kurume University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSUKE OKA
1Department of Surgery, Faculty of Medicine, Kurume University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAWANG DAE HONG
2Department of Surgery, Faculty of Medicine, Korea University Hospital, Guro-gu, Seoul, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUO SHIROUZU
1Department of Surgery, Faculty of Medicine, Kurume University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Metastatic recurrence of colon cancer in the left supraclavicular lymph node (Virchow lymph node) is rare, and to date there are no reports on radiotherapy as treatment. We report on a case of metastatic recurrence of sigmoid colon cancer in the Virchow lymph node with severe lymph node metastases successfully treated with a combined modality therapy of systemic chemotherapy and radiotherapy. The case is of a 58-year-old man, who underwent sigmoid excision and lymph node excision, and subsequently received systemic chemotherapy. After left supraclavicular lymph node recurrence appeared he later received radiotherapy. Complete response was achieved, and there has been no further recurrence, to date, 10 months after the radiotherapy. Radiotherapy was effective as a local treatment, and local control of distant metastasis of colonic cancer may lead to a good prognosis.

  • Colon cancer
  • Virchow lymph node metastasis
  • combination therapy

Chemoradiotherapy is widely used in Europe and America for rectal cancer before and after surgery. For any metastases from colonic cancer, systemic chemotherapy is often added in combination with surgery. Here we report on a case of combined systemic chemotherapy and radiotherapy for metastatic recurrence in the left supraclavicular (Virchow) lymph node.

Case Report

The case is of a 58-year-old man who presented with the main complaint of defecation trouble, diarrhea and stool pillar narrowness. On physical examination, the performance status (PS) was 0, there was no abdominal pain, and an elastic hard mass was palpable in the left lower quadrant of the abdomen. Colonoscopy showed type 2 advanced colonic cancer in the sigmoidal colon. A barium enema study showed irregular stenosis of approximately 3 cm from the sigmoidal colon (Figure 1). Computed tomography (CT) showed hypertrophy in the sigmoidal wall with a heterogeneous contrast effect and fluffing in the surrounding adipose tissue. The border with the small intestine was indistinct, and permeation was suspected. A small nodular shadow was suspected as being lymph node metastases in the adipose tissue around the tumor. Swelling in the para-aortic lymph nodes in the area of the superior mesenteric artery bifurcation suggested lymph node metastases (Figure 2). No metastasis was seen in the liver and lungs. The preoperative carcinoembryonic antigen level was 0.8 ng/ml. The preoperative diagnosis was sigmoidal colonic cancer, cSI, cN3, cH0, cP0, cM1 (para-aortic lymph node) cStageIV in the Japanese Classification of Colorectal Carcinoma (JCCC) (1).

Treatment strategy. To treat the passage disorder, we resected the primary tumor with palliative intent, and resected the para-aortic lymph node for histological examination. R2 surgery was achieved (para-aortic lymph node remained). We administered bevacizumab at 7.5 mg/kg and oxaliplatin at 130 mg/m2 on day 1 plus capecitabine at 1000 mg/m2 twice daily on days 1-14, every three weeks from postoperative day 21 as systemic chemotherapy.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

The barium enema study showed an irregular stenosis image of approximately 3 cm from the sigmoidal colon.

Pathological findings. The pathology results were poorly-differentiated adenocarcinoma, ly2, v2, lymph node metastasis: 3/17 (positive total), para aortic lymph node: 3/17 (positive total), pSS, pN1, cH0, pP0, pM1 (para aortic lymph node) fStage IV by JCCC (1) (Figure 2). Staining for epidermal growth factor receptor (EGFR) was positive on immunohistochemistry. V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) was wild type.

Episode of care. The patient received 11 cycles of capecitabine, oxaliplatin and bevacizumab therapy for para-aortic lymph node metastases. The best overall response was a partial response, and we then changed to FOLFIRI plus bevacizumab (bevacizumab at 5 mg/kg, irinotecan at 180 mg/m2, folinic acid at 400 mg/m2, fluorouracil (5-FU) bolus at 400 mg/m2 on day 1 and 5-FU continuous intravenous infusion at 1200 mg/m2 on days 1-2, every two weeks) due to onset of peripheral neuropathy grade 3. Peripheral neuropathy was improved by the four-cycle dosage of FOLFIRI plus bevacizumab to grade 1, and then we changed therapy to modified FOLFOX6 plus bevacizumab (bevacizumab at 5 mg/kg, oxaliplatin at 85 mg/m2, intravenous infusion folinic acid at 400 mg/m2, bolus 5-FU at 400 mg/m2 on day 1 and continuous intravenous infusion of 5-FU at 1200 mg/m2 on days 1-2, every two weeks) and FOLFIRI plus bevacizumab every four cycles (2). At 20 months postoperatively, metastasis in the left supraclavicular lymph node was detected on CT (Figure 4), on fluorodeoxyglucose positron-emission tomography (PET) (Figure 5), and on ultrasonograpy after 24 cycles in total. The abdominal para-aortic lymph node metastasis had disappeared. We started modified FOLFOX6 plus cetuximab [(250 mg/m2) on day 1, every week]. For the metastasis to the left supraclavicular lymph node, stable-disease status was achieved, and for other metastases, complete resposnse (CR) was achieved. However, we switched to tegafur, gimeracil, oteracil potassium (TS1) at 80 mg/day (two weeks administration, one week discontinuation) plus cetuximab at 250 mg/m2 (weekly) because we noticed protraction in peripheral neuropathy grade 2 and fatigue grade 1. The side-effect was relieved, and compliance was improved. After eight cycles, the metastasis to the left supraclavicular lymph node had increased to approximately 5 cm, with tenderness macroscopically. Surgical treatment was difficult anatomically, and so radiotherapy was performed. At 22 months postoperatively, this site was irradiated with 15 times of 3 Gy a total 45 Gy. Other sites of metastasis were controlled, and systemic chemotherapy was resumed. The symptoms were relieved immediately after radiotherapy, and there was reduction in tumor size. The tumor was gradually reduced and had disappeared macroscopically by day 48 after radiotherapy. We continued TS1 plus cetuximab, and the metastasis of the left supraclavicular lymph node disappeared on CT (Figure 4). No other metastasis was seen. There was no accumulation on PET (Figure 5). CR was maintained by 12 cycles of TS1+cetuximab administration in total. Because dermatopathy, paronychia, fatigue and diarrhea grade 1 appeared, we switched to TS1 alone. However, he was not able to receive it because diarrhea continued. We are following-up with no treatment, and CR has continued for more than 10 months. Figure 6 shows the clinical course.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Pathological findings: Macroscopic findings (A) and microscopic findings of poorly differentiated adenocarcinoma (B, ×40; C, ×200).

Discussion

For lymph node recurrence from colonic cancer, we remove the lymph nodes surgically if resectable, and if it is hard to resect, in the Japanese guidelines it is recommended that a case with PS 0-2 is given systemic chemotherapy and local treatment (3). Radiotherapy as the treatment for distant metastasis of colonic cancer is not often used for metastases other than to the brain or bone, because the site of the main distant metastasis is usually the liver. However, improvement in radiation exposure technology can suppress injury to normal tissue, and allows irradiation to a local site, so that a good effect from local treatment can be expected (4-7). We conducted irradiation for the purpose of pain relief in our case, but irradiation remarkably reduced the tumor, which subsequently disappeared on imaging. Other metastases were controlled by systemic chemotherapy, and CR was achieved generally. Radiotherapy is thought to be suitable as the local treatment instead of surgery in some cases.

As a third line of therapy, after failure of standard chemotherapy, a randomised study revealed a highly significant increase in median overall survival (OS) with cetuximab compared with best supportive care, from 4.8 months to 9.5 months, in patients with a KRAS wild-type tumor (8, 9). Administration of an antibody to EGFR for KRAS wild-type cancer is a novel made-to-order treatment, and no other markers are yet available. Research into such markers as amphiregulin is currently conducted (10). Thus, the development of an effective predictor marker of the outcome from radiotherapy is expected.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Computed tomographic findings of para aortic lymph node metastasis: prior to surgery (A), chemotherapy (B), and radiation therapy (C).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Computed tomographic findings of the metastasis to theVirchow lymph node: before radiation (A) and after radiation (B).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Fluorodeoxyglucose positron-emission tomographic findings. A: The left supraclavicular lymph node shows accumulation. B: There is no abnormal accumulation.

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

Treatmen course. Tegafur, gimeracil, oteracil potassium (TS1).

The lymphatic vessels including the thoracic duct arrives at the Virchow lymph node, and this is recognized as being the end node of lymph nodes (11). The prognosis of patients with stage IV colorectal carcinoma remains poor, with a median survival of just 9-10.3 months (12-15). The 5-year survival rate of patients with distant node-positive colonic cancer involving the para-aortic lymph node is approximately 3% (16). In the present case, the findings suggested that the number of metastatic organs was limited to only the one Virchow para-aortic lymph node. Treatment for colonic cancer usually involves the curative resection of the colonic tumor together with any metastasis in the lungs or peritoneum, to achieve a good prognosis and extend survival (17-20). If there is only one organ of metastasis, then survival can be extended in cases of colonic cancer using a combination of local treatment and systemic chemotherapy.

In the present case, radiotherapy was administered to metastasis in the Virchow lymph node, no other such report has been found in the literature. Radiotherapy can be considered as a strategic local treatment after using 5-FU, oxaliplatin, and irrinotecan. For metastatic recurrence of sigmoidal colonic cancer to the Virchow lymph node with severe lymph node metastases, we report our successful experience in one patient using combined systemic chemotherapy and radiotherapy. Radiotherapy was an effective local treatment, and the local control of distant metastasis of colonic cancer may lead to good prognosis.

Footnotes

  • This article is freely accessible online.

  • Received April 4, 2013.
  • Revision received June 7, 2013.
  • Accepted June 7, 2013.
  • Copyright© 2013 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Japanese Society for Cancer of the Colon and Rectum
    : Japanese Classification of Colorectal Carcinoma, Second English Edition. Kanehara & Co, Tokyo2009.
  2. ↵
    1. Oki E,
    2. Emi Y,
    3. Akagi Y,
    4. Tokunaga S,
    5. Sadanaga N,
    6. Tanaka T,
    7. Ogata Y,
    8. Saeki H,
    9. Kakeji Y,
    10. Baba H,
    11. Nishimaki T,
    12. Natsugoe S,
    13. Shirouzu K,
    14. Maehara Y
    : Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701). Oncology 84: 233-239, 2013.
    OpenUrlPubMed
  3. ↵
    1. Watanabe T,
    2. Itabashi M,
    3. Shimada Y,
    4. Tanaka S,
    5. Ito Y,
    6. Ajioka Y,
    7. Hamaguchi T,
    8. Hyodo I,
    9. Igarashi M,
    10. Ishida H,
    11. Ishiguro M,
    12. Kanemitsu Y,
    13. Kokudo N,
    14. Muro K,
    15. Ochiai A,
    16. Oguchi M,
    17. Ohkura Y,
    18. Saito Y,
    19. Sakai Y,
    20. Ueno H,
    21. Yoshino T,
    22. Fujimori T,
    23. Koinuma N,
    24. Morita T,
    25. Nishimura G,
    26. Sakata Y,
    27. Takahashi K,
    28. Takiuchi H,
    29. Tsuruta O,
    30. Yamaguchi T,
    31. Yoshida M,
    32. Yamaguchi N,
    33. Kotake K,
    34. Sugihara K,
    35. Japanese Society for Cancer of the Colon and Rectum
    : Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int Jo Clin Oncol 17: 1-29, 2012.
    OpenUrl
  4. ↵
    1. Kavanagh BD,
    2. Schefter TE,
    3. Cardenes HR,
    4. Stieber VW,
    5. Raben D,
    6. Timmerman RD,
    7. McCarter MD,
    8. Burri S,
    9. Nedzi LA,
    10. Sawyer TE,
    11. Gaspar LE
    : Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol 45: 848-855, 2006.
    OpenUrlCrossRefPubMed
    1. Lax I,
    2. Blomgren H,
    3. Naslund I,
    4. Svanstrom R
    : Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects. Acta Oncol 33: 677-683, 1994.
    OpenUrlCrossRefPubMed
    1. Onimaru R,
    2. Shirato H,
    3. Shimizu S,
    4. Kitamura K,
    5. Xu B,
    6. Fukumoto S,
    7. Chang TC,
    8. Fujita K,
    9. Oita M,
    10. Miyasaka K,
    11. Nishimura M,
    12. Dosaka-Akita H
    : Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 56: 126-135, 2003.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Uematsu M,
    2. Shioda A,
    3. Suda A,
    4. Fukui T,
    5. Ozeki Y,
    6. Hama Y,
    7. Wong JR,
    8. Kusano S
    : Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: A 5-year experience. Int J Radiat Oncol Biol Phys 51: 666-670, 2001.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Karapetis CS,
    2. Khambata-Ford S,
    3. Jonker DJ,
    4. O'Callaghan CJ,
    5. Tu D,
    6. Tebbutt NC,
    7. Simes RJ,
    8. Chalchal H,
    9. Shapiro JD,
    10. Robitaille S,
    11. Price TJ,
    12. Shepherd L,
    13. Au HJ,
    14. Langer C,
    15. Moore MJ,
    16. Zalcberg JR
    : KRAS mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765, 2008.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Holubec L,
    2. Liska V,
    3. Matejka VM,
    4. Fiala O,
    5. Dreslerova J,
    6. Mrazkova P,
    7. Treska V,
    8. Finek J
    : The role of cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res 32: 4007-4011, 2012.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Ohchi T,
    2. Akagi Y,
    3. Kinugasa T,
    4. Kakuma T,
    5. Kawahara A,
    6. Sasatomi T,
    7. Gotanda Y,
    8. Yamaguchi K,
    9. Tanaka N,
    10. Ishibashi Y,
    11. Miyamoto S,
    12. Kage M,
    13. Shirouzu K
    : Amphiregulin is a prognostic factor in colorectal cancer. Anticancer Res 32: 2315-2321, 2012.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Sato T
    (ed.): Color Atlas of Applied Anatomy of Lymphatics. Nankodo, Tokyo, 1997.
  10. ↵
    1. Joffe J,
    2. Gordon PH
    : Palliative resection for colorectal carcinoma. Dis Colon Rectum 24: 355-360, 1981.
    OpenUrlPubMed
    1. Liu SK,
    2. Church JM,
    3. Lavery IC,
    4. Fazio VW
    : Operation in patients with incurable colon cancer Is it worthwhile? Dis Colon Rectum 40: 11-14, 1997.
    OpenUrlCrossRefPubMed
    1. Makela J,
    2. Haukipuro K,
    3. Laitinen S,
    4. Kairaluoma MI
    : Palliative operations for colorectal cancer. Dis Colon Rectum 33: 846-850, 1990.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Sarela AI,
    2. Guthrie JA,
    3. Seymour MT,
    4. Ride E,
    5. Guillou PJ,
    6. O'Riordain DS
    : Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg 88: 1352-1356, 2001.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Johnston FM,
    2. Kneuertz PJ,
    3. Pawlik TM
    : Resection of non-hepatic colorectal cancer metastasis. J Gastrointest Oncol 3: 59-68, 2012.
    OpenUrlPubMed
  13. ↵
    1. Ambiru S,
    2. Miyazaki M,
    3. Ito H,
    4. Nakagawa K,
    5. Shimizu H,
    6. Kato A,
    7. Nakamura S,
    8. Omoto H,
    9. Nakajima N
    : Resection of hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 82: 274-278, 1998.
    OpenUrlCrossRefPubMed
    1. Murata S,
    2. Moriya Y,
    3. Akasu T,
    4. Fujita S,
    5. Sugihara K
    : Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 83: 1086-1093, 1998.
    OpenUrlCrossRefPubMed
    1. Sakamoto T,
    2. Tsubota N,
    3. Iwanaga K,
    4. Yuki T,
    5. Matsuoka H,
    6. Yoshimura M
    : Pulmonary resection for metastases from colorectal cancer. Chest 119: 1069-1072, 2001.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Takahashi K,
    2. Matsumoto H,
    3. Nakano D,
    4. Watanabe F,
    5. Oohinata R,
    6. Iwanaga T,
    7. Oohashi M,
    8. Iwasaki Y,
    9. Yamaguchi T
    : Is it necessary to carry out hepatic resection and pulmonary resection to obtain a cure for liver and lung metastases from colorectal cancer? Gan To Kagaku Ryoho 38: 187-192, 2011, (in Japanese).
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 33 (7)
Anticancer Research
Vol. 33, Issue 7
July 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Virchow Lymph Node Metastatic Recurrence of Sigmoid Colon Cancer with Severe Lymph Node Metastases Successfully Treated Using Systemic Chemotherapy Combined with Radiotherapy
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Virchow Lymph Node Metastatic Recurrence of Sigmoid Colon Cancer with Severe Lymph Node Metastases Successfully Treated Using Systemic Chemotherapy Combined with Radiotherapy
TAKAFUMI OHCHI, YOSHITO AKAGI, TETSUSHI KINUGASA, YOSHIAKI ISHIBASHI, NATSUKI TANAKA, SHINYA FUJINO, SHIRO KIBE, KOTARO YUGE, TERUO SASATOMI, TOMOAKI MIZOBE, YOSUKE OKA, KAWANG DAE HONG, KAZUO SHIROUZU
Anticancer Research Jul 2013, 33 (7) 2935-2940;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Virchow Lymph Node Metastatic Recurrence of Sigmoid Colon Cancer with Severe Lymph Node Metastases Successfully Treated Using Systemic Chemotherapy Combined with Radiotherapy
TAKAFUMI OHCHI, YOSHITO AKAGI, TETSUSHI KINUGASA, YOSHIAKI ISHIBASHI, NATSUKI TANAKA, SHINYA FUJINO, SHIRO KIBE, KOTARO YUGE, TERUO SASATOMI, TOMOAKI MIZOBE, YOSUKE OKA, KAWANG DAE HONG, KAZUO SHIROUZU
Anticancer Research Jul 2013, 33 (7) 2935-2940;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case Report
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Feasibility of an Exercise Training Program Among Patients With Newly Diagnosed Advanced Breast Cancer
  • Impact of Surgery Refusal on Overall Survival in Merkel Cell Carcinoma
  • Association of County-level Social Determinants and Pancreatic Cancer Incidence in the United States
Show more Clinical Studies

Similar Articles

Keywords

  • colon cancer
  • Virchow lymph node metastasis
  • combination therapy
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire